DrugPatentWatch Database Preview
Drugs in Development Information for VTP-194204
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the development status for investigational drug VTP-194204?
VTP-194204 is an investigational drug.
There have been 17 clinical trials for VTP-194204.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 21st 2019.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Psoriasis, and Erectile Dysfunction. The leading clinical trial sponsors are Steba Biotech S.A., Vitae Pharmaceuticals, Inc., and STEBA France.
There are seventeen US patents protecting this investigational drug and fifty-two international patents.
Summary for VTP-194204
| US Patents | 17 |
| International Patents | 52 |
| US Patent Applications | 33 |
| WIPO Patent Applications | 9 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2019-01-21) |
| Vendors | 8 |
Recent Clinical Trials for VTP-194204
| Title | Sponsor | Phase |
|---|---|---|
| Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer | Steba Biotech S.A. | Phase 3 |
| Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate Cancer | International Drug Development Institute | Phase 4 |
| Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate Cancer | PrimeVigilance LTD | Phase 4 |
Clinical Trial Summary for VTP-194204
Top disease conditions for VTP-194204
Top clinical trial sponsors for VTP-194204
US Patents for VTP-194204
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| VTP-194204 | Start Trial | Autoimmune disorder treatment using RXR agonists | lo Therapeutics, Inc. (Santa Ana, CA) | Start Trial |
| VTP-194204 | Start Trial | Treatment of cancer with specific RXR agonists | Io Therapeutics, Inc. (Santa Ana, CA) | Start Trial |
| VTP-194204 | Start Trial | Treatment of cancer with specific RXR agonists | IO Therapeutics, Inc. (Santa Ana, CA) | Start Trial |
| VTP-194204 | Start Trial | Autoimmune disorder treatment using RXR agonists | IO Therapeutics, Inc. (Santa Ana, CA) | Start Trial |
| VTP-194204 | Start Trial | Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones | IO Therapeutics, Inc. (Santa Ana, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for VTP-194204
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| VTP-194204 | Australia | 2012352149 | 2031-12-13 | Start Trial |
| VTP-194204 | Australia | 2017210644 | 2031-12-13 | Start Trial |
| VTP-194204 | Canada | 2858882 | 2031-12-13 | Start Trial |
| VTP-194204 | China | 104114171 | 2031-12-13 | Start Trial |
| VTP-194204 | China | 110151745 | 2031-12-13 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
